Schering Corporation

Merck Sharp + Dohme Corp.

Latent Heat Solutions, LLC

Other

Td Ameritrade IP Compnay, Inc.

Ada Technologies, Inc.

Schering-plough Corporation

Global Web Horizons, LLC

Joseph Michael Kelly

Adriano Afonso

Ronald J Doll

Arthur G Taveras

Alan B Cooper

Mark Henry Hartmann

Alan K Mallams

Ronald L Wolin

F George Njoroge

Viyyoor Moopil Girijavallabhan

Samuel Chackalamannil

Timothy J Guzi

Stacy W Remiszewski

Gerald Wayne Shipps, Jr

Dinanath F Rane

Yongqi Deng

Jay Weinstein

Neng-Yang Shih

Stuart B Rosenblum

Pauline C Ting

Xiaolei Gao

Andrew William Stamford

Joseph A Kozlowski

Stuart W McCombie

Wensheng Yu

Vincent Stewart Madison

M Arshad Siddiqui

Michael Berlin

Ying Huang

Corey Strickland

Younong Yu

Jian Liu

Alan W Hruza

Li Xiao

William J Greenlee

Amjad Ali

Xianhai Huang

Dong Xiao

Kevin J Wilson

Michael Man-Chu Lo

Phieng Siliphaivanh

Christopher W Boyce

Sunil Paliwal

Eric J Gilbert

Yusheng Wu

Tong Wang

Jagdish A Desai

James J-s Wang

Jianping Chao

Hugh Y Zhu

Sobhana Babu Boga

Liang Zhu

Abdul-Basit Alhassan

Youhao Dong

Carmen S Alvarez

Yeon-Hee Lim

Jayaram R Tagat

Robert Sun

Tarik Lalwani

Cynthia J Aki

Yang Nan

Johan A Ferreira

Sie-Mun Lo

Xin Yao

Umar Faruk Mansoor

Rongze Kuang

Rajan Anand

Christian Fischer

Tao Yu

Hon-Chung Tsui

Matthew H Daniels

Qiaolin Deng

Junying Zheng

Scott E Wolkenberg

Paul Tempest

Dane James Clausen

Wei Zhou

Binyuan Sun

Heping Wu

Nicolas Zorn

Corey E Bienstock

Walter Won

Deyou Sha

Ahmed Abdi Samatar

Gang Zhou

Mehul F Patel

Weibing Xing

Xiaohua Huang

Jianhua Cao

Gerald W Shipps

Brendan O'Boyle

Adam J Schell

Jae-Hun Kim

Hongwu Wang

Hyunjin M Kim

Gioconda V Gallo

Azim Alan Celebi

Gioconda V Gallo-Etienne

Joseph Michael Lawless Kelly

The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, R, R, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.

Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing cancer, inflammation, neurodegeneration disease and/or diabetes in a subject.

Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: 'Z' and Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Substituted imidazo[1,2-c]quinazolines as A2A antagonists

A casing for the thermal management and protection of an electrochemical cell, the casing comprises a first material, an inner surface configured to be in physical contact with an electrochemical cell, wherein the inner surface is substantially solid at room temperature; and a polymer matrix dispersed within the first material and comprising two or more temperature management materials. At least one of the two or more temperature management materials comprise a phase change material having a latent heat of at least 5 Joules per gram and a transition temperature between 0&#xb0; C. and 100&#xb0; C., and an elastomeric material. The polymer matrix is substantially homogeneous, and in an environment where the electrochemical cell and a second electrochemical cell operate under the same charging and discharging conditions, the casing reduces a first operating temperature of the electrochemical cell by at least 10&#xb0; C.

Systems, structures and materials for electrochemical device thermal management

Battery container

Disclosed herein are systems and methods for the detection of alterations in glucose metabolism in a subject. The disclosed methods and systems provide, in certain embodiments, administering a first eye test to the subject when the subject is in a normal state, obtaining a first set of one or more images of the first eye test of the subject, administering a second eye test to the subject and obtaining a second set of one or more images of the second eye test of the subject. The methods further provide for analyzing one or more differences identified between the first set of one or more images and the second set of one or more images.

Methods and systems for the detection of disease

This disclosure provides casings and materials for the thermal management and protection of an electrochemical cell. The casing may also comprise a composite polymeric material for electrochemical cell thermal management, the composite polymeric material comprising a crosslinked polyether polyol phase change material configured to be in physical contact with at least a portion of an electrochemical cell.

This disclosure provides a casing for the thermal management and protection of an electrochemical cell. The casing may comprise an inner surface configured to be in physical contact with at least a portion of an outer surface of an electrochemical cell. The inner surface may be substantially solid at room temperature. The casing may also comprise a polymer matrix which itself comprises two or more temperature management materials. At least one of the two or more temperature management materials may comprise a microencapsulated phase change material having a latent heat of at least 5 Joules per gram and a transition temperature between 0&#xb0; C. and 100&#xb0; C., and at least one other of the two or more temperature management materials may comprise an elastomeric material. The polymer matrix may be substantially homogeneous.

A process is provided for synthesizing a lithium, nickel, manganese and oxygen composition, LiNiMnO, where w is from about 0.8 to about 1.2, x is from about 0.3 to about 0.8, y is from about 1.3 to about 1.8, and z is from about 3.8 to about 4.2. The composition has a lattice parameter 'a' value and wt % crystalline spinel value within the bounds defined by the following lattice parameter 'a' and wt % crystalline spinel coordinate values of about (8.1690 &#x212b;, 98.5%), about (8.1765 &#x212b;, 98.5%), about (8.1810 &#x212b;, 96.2%), about (8.1810 &#x212b;, 93.4%), about (8.1771 &#x212b;, 93.4%), and about (8.1690 &#x212b;, 97.6%).

[object Object]

Disclosed are compounds of Formula A: (structurally represented) where 'RG1', 'RG2a', &#x201c;RG4&#x201d;, &#x201c;RG5&#x201d;, &#x201c;MG1&#x201d;, &#x201c;n&#x201d; and &#x201c;m&#x201d; are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. 

Disclosed herein are system, method, and computer program product embodiments for crowdsourcing e-mail filtering. An embodiment operates by receiving an input from a community member indicating that an e-mail received by the community member is unwanted, counting a number of inputs received from community members indicating that e-mail is unwanted based on one or more criteria, flagging future e-mails based on the criteria when the number of inputs counted reaches a threshold for penalizing an originator or a group associated with the originator of the unwanted e-mail, and denying delivery of future e-mails from the originator or the group associated with the originator until a penalty period expires.

Crowdsourcing e-mail filtering

Growing community of inventors

Parlin, NJ, United States of America

Joseph Michael Kelly